安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- Alnylam® Pharmaceuticals
Learn about Alnylam Pharmaceuticals, RNAi therapeutics, and the company's efforts in treating amyloidosis, hyperoxaluria, and porphyria
- Alnylam Pharmaceuticals - Wikipedia
Alnylam Pharmaceuticals, Inc is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics [3] for genetically defined diseases The company was founded in 2002 and is headquartered in Cambridge, Massachusetts [4]
- Alnylam Pharmaceuticals Press Release | Jun 18, 2025 | Alnylam . . .
About Alnylam Pharmaceuticals Alnylam (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and prevalent diseases with unmet need Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful
- Alnylam® Pharmaceuticals—Laboratoire leader de lARNi thérapeutique . . .
Créée en 2002, la société Alnylam concrétise une vision audacieuse selon laquelle des possibilités scientifiques peuvent devenir une réalité en s’appuyant sur une solide plateforme de découverte et un large portefeuille de médicaments expérimentaux
- Alnylam® Pharmaceuticals—The Leading RNAi Therapeutics Company | Canada
Alnylam’s pioneering science has yielded the critical breakthroughs and innovations that have made RNA interference (RNAi)-based medicines a reality We ushered in the first phase of the RNAi RevolutionTM by developing the first five approved RNAi therapeutics
- Alnylam Receives European Commission Approval for AMVUTTRA
About Alnylam Pharmaceuticals Alnylam (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of
- Alnylam Pharmaceuticals - Crunchbase Company Profile Funding
Alnylam Pharmaceuticals focuses on RNA interference (RNAi) as a method for developing drugs to treat rare genetic diseases Genetic Medicines: The company's pipeline includes investigational RNAi therapeutics for genetic diseases Cardio-metabolic Diseases: Alnylam is developing treatments for cardio-metabolic diseases using RNAi technology
- Clinical Development Pipeline | Alnylam® Pharmaceuticals
Through pioneering science and an unwavering commitment to patients, Alnylam has led the translation of the breakthrough discovery of RNA interference (RNAi) into an entirely new class of medicines that is disrupting disease
|
|
|